Method
Level · gp.fundamentals.debt_to_revenue
Raw value 223.17% · OPTIONAL
· Surgical & Medical Instruments & Apparatus
RESEARCH SNAPSHOTICU MEDICAL INC/DE's latest supported as-filed period reports revenue of $551.7M, 0.5% above the comparable as-filed period; gross margin moved 470 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 223.17% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 3.36% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 14.53% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 0.51% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 110.10% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 42.61% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 0.5%; Operating margin moved 516 bp higher; Operating income increased 269.6%.
3 evidence-backed componentsOperating margin changed +516 basis points from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
ICUI · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001669639-26-000004SEC ↗4Sep 1, 2026Period Sep 1, 20260001804831-26-000006SEC ↗4Aug 31, 2026Period Aug 31, 20260001804831-26-000005SEC ↗4Aug 13, 2026Period Aug 13, 20260001698998-26-000004SEC ↗4Aug 12, 2026Period Aug 12, 20260002013412-26-000003SEC ↗4Aug 11, 2026Period Aug 11, 20260001727477-26-000003SEC ↗4Aug 11, 2026Period Aug 11, 20260001217439-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 3, 2026Filed Sep 3, 2026 | Sanzone Virginia RuthVP, General Counsel | Open Market SaleDirect | 2,202 | $168 | $369,203 | Form 4 ↗ |
| Sep 3, 2026Filed Sep 3, 2026 | Sanzone Virginia RuthVP, General Counsel | Open Market SaleDirect | 1,238 | $168 | $208,523 | Form 4 ↗ |
| Sep 3, 2026Filed Sep 3, 2026 | Sanzone Virginia RuthVP, General Counsel | Open Market SaleDirect | 724 | $170 | $122,736 | Form 4 ↗ |
| Sep 3, 2026Filed Sep 3, 2026 | Sanzone Virginia RuthVP, General Counsel | Open Market SaleDirect | 692 | $172 | $118,688 | Form 4 ↗ |
| Sep 1, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 7.09% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 4.12% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 2.15% · OPTIONAL
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Gross margin changed +470 basis points from the comparable as-filed period.
Operating income changed +269.6% from the comparable as-filed period.
Net income changed -46.0% from the comparable as-filed period.
Inventory / revenue changed -221 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Revenue changed +0.5% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Gross profit changed +13.0% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000883984-26-000041| Bonnell Brian MichaelChief Financial Officer |
| Open Market SaleDirect |
| 6,381 |
| $175 |
| $1.1M |
| Form 4 ↗ |
| Aug 31, 2026Filed Aug 31, 2026 | Bonnell Brian MichaelChief Financial Officer | Open Market SaleDirect | 1,712 | $171 | $292,843 | Form 4 ↗ |
| Aug 31, 2026Filed Aug 31, 2026 | Bonnell Brian MichaelChief Financial Officer | Open Market SaleDirect | 1,914 | $172 | $329,443 | Form 4 ↗ |
| Aug 31, 2026Filed Aug 31, 2026 | Bonnell Brian MichaelChief Financial Officer | Open Market SaleDirect | 4,568 | $173 | $792,291 | Form 4 ↗ |
| Aug 31, 2026Filed Aug 31, 2026 | Bonnell Brian MichaelChief Financial Officer | Open Market SaleDirect | 1,113 | $174 | $193,567 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 13, 2026 | Woolson DanielVP, GM-Infusion Capital | Open Market SaleDirect | 5,417 | $181 | $982,265 | Form 4 ↗ |